Can an adult with stable angina taking ranolazine (CYP3A4‑metabolized) and normal liver function, without concurrent strong CYP3A4 inhibitors or other QT‑prolonging drugs, safely consume one standard glass of wine per month?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 21, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can a Person on Ranolazine Safely Consume One Glass of Wine Monthly?

Yes, consuming one standard glass of wine per month is safe for an adult with stable angina taking ranolazine, provided they have normal liver function and are not taking strong CYP3A4 inhibitors or other QT-prolonging medications.

Rationale for Safety

Hepatic Metabolism and Alcohol Interaction

  • Ranolazine undergoes extensive hepatic metabolism primarily via CYP3A4, but the drug is absolutely contraindicated only in patients with documented liver cirrhosis or hepatic impairment 1, 2.

  • A single glass of wine consumed once monthly represents minimal, intermittent alcohol exposure that does not constitute chronic alcohol use or cause acute hepatic impairment in individuals with normal baseline liver function 1.

  • Plasma ranolazine levels increase 50-60% in patients with moderate hepatic impairment, but occasional, modest alcohol consumption does not produce this degree of sustained hepatic dysfunction 1.

QT Prolongation Considerations

  • Ranolazine causes dose-related QT interval prolongation through inhibition of the rapid delayed rectifier potassium current (IKr), but torsades de pointes has not been observed at therapeutic doses 1, 2.

  • The primary concern with alcohol and ranolazine would be additive QT prolongation, but moderate alcohol consumption (one standard drink) does not significantly prolong QT interval in patients without underlying electrical instability 3.

  • Ranolazine is contraindicated in patients with pre-existing QT-prolonging conditions or electrical instability, but not in patients who occasionally consume small amounts of alcohol 3.

Critical Precautions

Absolute Contraindications to Consider

  • Liver cirrhosis or hepatic impairment remains an absolute contraindication to ranolazine use, regardless of alcohol consumption 1, 2.

  • Patients with pre-existing QT prolongation or R-on-T phenomena should not take ranolazine at all 3.

Drug Interaction Monitoring

  • Ensure the patient is not taking strong CYP3A4 inhibitors (diltiazem, verapamil, ketoconazole, itraconazole, clarithromycin, erythromycin) which would significantly increase ranolazine plasma levels 4.

  • Monitor for interactions with digoxin, as ranolazine increases digoxin plasma concentrations and the combination requires dose adjustment 1, 2.

Hemodynamic Stability

  • Ranolazine has a hemodynamically neutral profile and does not significantly affect heart rate or blood pressure, unlike traditional antianginal agents 1, 2, 5.

  • This neutral profile means that the mild vasodilatory effects of one glass of wine monthly are unlikely to cause clinically significant hypotension when combined with ranolazine 2.

Common Pitfalls to Avoid

  • Do not confuse occasional modest alcohol use with chronic alcohol consumption or binge drinking, which can cause hepatic impairment and would be contraindicated 1.

  • Do not assume all alcohol is prohibited—the contraindication is based on hepatic impairment, not alcohol per se 2.

  • Verify baseline liver function before initiating ranolazine and periodically thereafter, especially if alcohol consumption increases 1.

  • Screen for other QT-prolonging medications that might create additive risk when combined with ranolazine and alcohol 3.

Clinical Monitoring

  • Patients should be counseled that while one glass of wine monthly is safe, escalating to regular or heavy alcohol consumption would require reassessment of ranolazine therapy 1.

  • Monitor for common ranolazine adverse effects (dizziness, constipation, nausea, headache) which could theoretically be exacerbated by alcohol, though this is unlikely with such infrequent, modest consumption 6, 7, 8.

References

Guideline

Mechanism of Action of Ranolazine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Ranolazine for Chronic Angina Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Ranolazine Use in R-on-T ECG Patterns

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Advances in the management of stable angina.

Journal of managed care pharmacy : JMCP, 2006

Research

Ranolazine for chronic stable angina.

Lancet (London, England), 2008

Research

Ranolazine: effects on ischemic heart.

Recent patents on cardiovascular drug discovery, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.